$999 – $1,649

6th World Congress and Exhibition on Antibiotics and Antibiotic Resistance...

Event Information

Share this event

Date and Time

Location

Location

Venue will be informed to the Registered Participants

London

United Kingdom

View Map

Refund Policy

Refund Policy

No Refunds

Event description

Description

6th World Congress and Exhibition on Antibiotics and Antibiotic Resistance

About Conference
Antibiotics 2019 invites all the participants from all over the world to attend ‘6th World Congress and Exhibition on Antibiotics and Antibiotic Resistance' to be held on June 03-04, 2019 London, UK which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

We organize a series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Why to attend?

Antibiotics 2019 is a platform to discuss and learn about the latest advancements in the field of Antibiotics and Antibiotic Resistance as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance.

The 2-day conference gathers researchers, academia, labs, Drug Manufacturers, government agencies, health professionals, hospitals, young investigators, pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the Antibiotic resistance problem.

Sessions/ Tracks

After a successful conference of Antibiotics 2018, we are currently bringing forth “6th World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2019) slated on June 03-04, 2019 at London, UK. Antibiotics 2019 aims to gather the most elegant societies and industries along with the renowned and honorable persons from top universities across the globe.

Antibiotics 2019 covers various aspects of Antibiotics, The Emergency of Antimicrobial resistance, Different Types of Antibiotics, Applications of Antibiotics, Antibiotic Resistance: Opportunities and Challenges, Antibiotics for Various Diseases and Infections, Antibiotic Prophylaxis, Antibiotics: In Pregnancy and Lactation, Antibiotics in Different Industries, Modern Antibiotics: Emerging trends, Barriers and Opportunities, Drug Discovery and Novel Delivery Technologies, Antibiotics for Emerging and Re-emerging Diseases, Micro Organisms in Recent Drug Discovery, Clinical Trials of Antibiotics, Antibiotics and Mechanism, Antibiotic Regulatory Affairs and Antibiotics Market Analysis and Business Opportunities.

Track 1: Antibiotics

Antibiotics are a type of antimicrobials that are used in treatment and prevention of bacterial infections. They may kill or inhibit the growth of bacteria. Many antibiotics are also effective against protozoans and fungi; some are toxic to humans and animals also, even when given in therapeutic dosage. Antibiotics are not effective against viruses such as common cold or influenza, and may be harmful when taken inappropriately. Physicians must ensure the patient has a bacterial infection before prescribing antibiotics.

Track 2: The Emergence of Antimicrobial Resistance

Antibiotic resistance invoke especially to the resistance to antibiotics that occurs in common bacteria that cause infection. The easy approach and capability of Antibiotics led to overuse in live-stock raising promotes bacteria to flourish resistance. This led to comprehensive problems with antibiotic resistance. World Health Organization (WHO) classified antimicrobial resistance as a serious hazard and no longer a indicator for the future. Antibiotic resistance is now among every part of the world and its stirring everyone irrespective to the age. When infections become resistant to first-line drugs, more costly therapies must be used. A longer duration of illness and treatment, often in hospitals, increases health care costs as well as the financial burden on families and societies. To help prevent the development of current and future bacterial resistance, it is essential to prescribe antibiotics according to the principles of antimicrobial stewardship, such as specify antibiotics only when they are needed.

Track 3: Antibiotic Resistance: Opportunities and Challenges

Certain bacterial infections now oppose all antibiotics. The resistance problem may be reversible, but only if society begins to acknowledge how the drugs affect "good" bacteria as well as "bad". Historically, most antibacterials were used in hospitals, where they were integrated into surgical clothes and soaps to limit the spread of infection. More recently, however, those substances (including triclosan, triclocarbon and such quaternary ammonium compounds as benzalkonium chloride) have been mixed into lotions, dish-washing detergents and soaps meant for general consumers. They have also been impregnated into such items as cutting boards, toys, high chairs and mattress pads.

Track 4: Different Types of Antibiotics

Antibiotics are also noted as antibacterials, are types of medications that destroy or slow down the growth of bacteria. Alexander Fleming discovered first penicillin, the first chemical compound with antibiotic properties. Some of the common antibiotics are Aminoglycosides, Cephalosporins, Carbapenems, Macrolides, Penicillin, Quinolones, Sulfonamides and, Tetracyclines etc. General fundamentals of antibiotic prescribing are use: First-line antibiotics first, Reserve broad spectrum antibiotics for marked circumstances only, prescribe antibiotics for bacterial infections if Symptoms are significant or severe.

Track 5: Applications of Antibiotics

Choice of relevant antibiotics is presently based on individual patient need. Preservation of bacterial sensitivity needs perceptive of how antibiotics select resistance. ‘Ten commandments’ which might be considered carefully when a preference has to be made for antibiotic prescribing. The compelling importance of the fact that all healthcare personnel should take ownership of the need to specify accordingly and to practice effective infection control. A realization that antibiotics may not be competent for the tasks required of them and eventually, with widespread resistance, may be incapable of the task they do today.

Track 6: Antibiotics for Various Diseases and Infections

Antibiotics are amidst the most regularly recommended medications in modern medicine. Antibiotics are useless against viral infections. When you take antibiotics, follow the guidelines carefully. It is important to finish your medicine even if you feel improved. If you stop treatment too soon, some bacteria may survive and re-infect you. Do not save antibiotics for later or use someone else's prescription.

Track 7: Antibiotic Prophylaxis

Antimicrobial prophylaxis is generally used by clinicians for the prevention of numerous infectious diseases. Optimal antimicrobial agents for prophylaxis should be nontoxic, inexpensive, bactericidal and active against the typical pathogens that can motive surgical site infection postoperatively. To maximize its effectiveness, intravenous perioperative prophylaxis should be carried out within 30 to 60 minutes before the surgical incision. Antimicrobial prophylaxis should be of short time to downturn toxicity and antimicrobial resistance and to reduce cost.

Track 8: Antibiotics: In Pregnancy and Lactation

Antibiotics are frequently recommended during pregnancy. The specific medication must be chosen carefully, however. Some antibiotics are prescribed to take during pregnancy, while others are not. Safety depends on various factors, including the type of antibiotics, when in pregnancy you take the antibiotic, how much you take and for how long. Antibiotics normally advised safe during pregnancy: Ampicillin, Amoxicillin, Clindamycin, Erythromycin, Penicillin, Nitrofurantoin. Despite there's no direct clue that these antibiotics cause birth defects, additional research is needed. In the interim, use of these medications is still assured in some cases.

Track 9: Antibiotics in Different Industries

Antibiotics must be used accordingly in humans and animals because both uses share to the emergence, persistence, and escalation of resistant bacteria. Resistant bacteria in food-producing animals are of particular concern. Food animals play as a source of resistant pathogens and resistance mechanisms that can directly or indirectly result in antibiotic resistant infections in humans. Resistant bacteria may be transmitted to humans through the foods we eat. Some bacteria have turned resistant to more than one sort of antibiotic, which makes it more difficult to treat the infections they cause. Sustaining the efficiency of antibiotic drugs is vital to insulating human and animal health.

Track 11: Drug Discovery and Novel Delivery Technologies

In the prior most drugs have been invented either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new access has been to recognize how disease and infection are controlled at the molecular and physiological level and to mark specific entities based on this knowledge. The process of drug discovery involves the identification of candidates, characterization, screening, synthesis, and assays for therapeutic efficacy. Evolution of an existing drug molecule from a ordinary form to a novel delivery system can significantly improve its performance in terms of patient compliance, efficacy and safety. These days, drug delivery companies are engaged in the development of numerous platform technologies to get ambitious advantage, extend patent life, and increase market share of their products. Formerly a compound has displayed its value in these tests; it will begin the process of drug development prior to clinical trials.

Track 12: Antibiotics for Emerging and Re-emerging Diseases

New diseases are originating globally and old diseases are re-emerging as Infectious agents evolve or spread, and as changes occur in conservation, socio-economic conditions, and population patterns. Likewise, many diseases thought to be decently controlled appear to be making a revival. In developed countries, public health measures such as sewage treatment, vaccination programs, sanitation and access to good medical care-including a wide range of antibiotics-have virtually disposed traditional diseases such as tuberculosis, diphtheria and whooping cough.

Track 13: Micro Organisms in Recent Drug Discovery

Environmental microbes are a leading source of drug discovery, and several microbial products (anti-tumor products, antibiotics, immune suppressants and others) are used frequently for human therapies. Most of these products were accessed from cultivable (<1%) environmental microbes, means that the large number of microbes were not targeted for drug discovery. With the onset of new and emerging technologies, we are poised to harvest novel drugs from the so-called 'uncultivable' microbes. Multidisciplinary way of linking different technologies can assist and reform drug discovery from uncultivable microbes and inspect the current cramp of technologies and scenario to swamp such constraints that might further expand the promise of drugs from environmental microbes.

Track 14: Clinical Trials of Antibiotics

Prescribing doctors are, progressively, using clinical trial data as a major source of information for evidence-based medicine for the remedy of infectious diseases, as in other clinical disciplines. However, it may be difficult to excerpt from these data the material that is needed for the management of the individual patient. At the same time, clinical trial testimony have been used, probably satisfactorily, in the process of drug registration, and the pharmaceutical industry has spent progressively large amount of money to satisfy the needs of this process. In the face of all these problems, switch in the way antibiotic clinical trials are designed and performed are clearly necessary, although this must not disturb the balance so far as to restore them less useful for those who currently derive greatest benefit from them.

Track 15: Antibiotics and Mechanism of Action

Antibacterial action customarily falls within one of four mechanisms, three of which involve the inhibition or regulation of enzymes tangled in cell wall biosynthesis, nucleic acid metabolism and repair, or protein synthesis, respectively. The fourth mechanism associates the interruption of membrane structure. Many of these cellular functions targeted by antibiotics are most effective in multiplying cells. Since there is often overlap in these functions between eukaryotic mammalian cells and prokaryotic bacterial cells, it is not surprising that some antibiotics have also been found to be useful as anticancer agents.

Track 16: Antibiotic Regulatory Affairs

Regulatory affairs (RA), are also called as government affairs, is a profession within regulated industries, such as medical devices, pharmaceuticals etc. Regulatory affairs also have a very specific meaning within the healthcare industries (medical devices, functional foods, biologics and pharmaceuticals). Regulatory affairs (medical affairs) professionals (aka regulatory professionals) generally have the duty for the following general areas: Ensuring that the companies obey with all of the regulations and laws pertaining to their business.

Track 17: Antibiotics: Market Analysis and Business Opportunities

The global antibiotics market was valued at $39.6 billion in 2013 and is expected to reach $41.2 billion by 2018, at a CAGR of 0.8%. From, 2005 this market is seen to grow at an annual rate of 6.6% until 2011. There are many companies producing antibiotics these days and there are many other antibiotics present in the market such as aminoglycoside antibiotics and it cap around 79% of the global demand. Moreover, the other antibiotics such as penicillin have 8%, streptomycin 1%, chloramnphenicol 1 %, tetracyclines 4%, erythromycin has 7%, market.

AGENDA

SCIENTIFIC PROGRAM
Monday, 03rd June DAY 1

08:30-09:00 Registrations
09:00-09:30 Introduction
09:30-09:50 COFFEE BREAK
09:50-11:50
Meeting Hall 01 KEYNOTE LECTURES
MEETING HALL 01 MEETING HALL 02
11:50-13:10 Talks On:
Antibiotics
Talks On:
Antibiotics and Mechanism of Action
Introduction to antibiotic uses and challenges Broad spectrum
Basic principles of prescribing antibiotics Narrow spectrum
Mechanisms of bacteriostatic or
bactericidal action Nuclear material
Pharmacokinetics of Antibiotics
Pharmacodynamics of Antibiotics
13:10-13:15 GROUP PHOTO
13:15-14:00 LUNCH BREAK
MEETING HALL 01 MEETING HALL 02
14:00-16:00 Talks On: Different Types of Antibiotics and
their Applications
Talks On: Micro Organisms in Recent
Drug Discovery
Hypocholesterolemic agents Novel species discovery
Immunosuppressive agents Micos from different areas (patients,
geographical locations)
Anti-migraine agents Geneticlly modified organisms
Anti-bacterials
Antifungals
Penicillins
16:00-16:20 COFFEE BREAK

SCIENTIFIC PROGRAM
Tuesday, 04th June DAY 2

09:00-10:30
Meeting Hall 01 KEYNOTE LECTURES
10:30-10:50 COFFEE BREAK
MEETING HALL 01 MEETING HALL 02
10:50-12:50 Talks On:
The Emergence of Antimicrobial Resistance
Talks On:
Antibiotic Resistance: Opportunities and
Challenges
Antimicrobial Stewardship Antibiotics and alternatives
Bacterial antibiotic resistance Systemic intervention – values, conflict and blue
room resolution
Mechanism of antimicrobial resistance Grand challenges – antimicrobial resistance
Proteomics of antimicrobial resistance Intervention against antimicrobial resistance
– approaches and implementation
Antimicrobial resistance
A public approach to antimicrobial resistance
12:50-13:35 LUNCH BREAK
MEETING HALL 01 MEETING HALL 02
13:35-15:55 Talks On:
Drug Discovery and Novel Delivery
Technologies
Talks On:
Antibiotics for Emerging and Re-emerging
Diseases
Policies to stimulate drug development and
discovery Resistance and re-emerging theories
Role of computational biology Medication procedures
Ligand binding studies Molecular mechanism of resistance
Transport (simulation studies) New drugs for emerging diseases
Molecule mediating transport
15:55-16:15 COFFEE BREAK
MEETING HALL 01 (16:15-17:00) MEETING HALL 01 (17:00-18:00)
Poster Presentations Workshop
Awards & Closing Ceremony

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorship

NO REFUNDS ALLOWED ON REGISTRATIONS
Prices may go up any time. Service fees included in pricing.
-----------------------------------------------------------------
This event is brought to you by:
Conference Series - NewYorkEventsList
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com
-----------------------------------------------------------------

VIO181210CRE

Share with friends

Date and Time

Location

Venue will be informed to the Registered Participants

London

United Kingdom

View Map

Refund Policy

No Refunds

Save This Event

Event Saved